Bulimia Nervosa Market Research Report: Information by Disorder Type (Purging and Non-Purging), Drug Type (Antidepressants, Antipsychotics, and Others), Route of Administration (Oral, Intravenous, and Others), End User (Hospitals & Clinics, Homecare Settings, Specialty Centers, and Others), and Region (the Americas, Europe, Asia-Pacific, and the Middle East & Africa)—Forecast till 2027

Bulimia Nervosa Market Scenario

The bulimia nervosa market is expected to exhibit significant growth over the forecast period. The market was valued at approximately USD 429.84 million in 2018 and is projected to register a 4.9% CAGR over the forecast period. Bulimia nervosa is an eating disorder that is characterized by eating a large amount of food (binge eating) in a short period. The disorder is also known as bulimia. Bulimia nervosa may cause various life-threatening and serious complications, such as heart problems, tooth & gum decay, anxiety, self-injury, dehydration, and digestive problems. Factors such as the rising prevalence of psychological disorders, alcoholism, and diabetes are expected to drive market growth. According to an article published by the National Alliance on Mental Illness (NAMI), 19.1% adults in the US experienced mental illness in 2018. Moreover, drastically changing lifestyle is also expected to boost market growth. However, factors such as the lack of drugs specifically for the treatment of bulimia nervosa and lack of awareness regarding the treatment options are expected to hamper the market growth.   

Segmentation

The bulimia nervosa market has been segmented into disorder type, drug type, route of administration, end user, and region. Based on disorder type, the bulimia nervosa market has been divided into purging and non-purging. The bulimia nervosa market, by drug type, has been segmented into antidepressants, antipsychotics, and others. Based on route of administration, the bulimia nervosa market is segmented into oral, intravenous, and others. The bulimia nervosa market, by end user, has been segmented into hospitals & clinics, home care settings, specialty centers, and others. The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The bulimia nervosa market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada. The European bulimia nervosa market has been segmented into Western Europe and Eastern Europe. The market in Western Europe has further been classified as France, Germany, Spain, the UK, Italy, and the rest of Western Europe.  The bulimia nervosa market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Middle East & Africa bulimia nervosa market is segmented into the Middle East and Africa.    

Key Players

Allergan, Inc. (Ireland), Eli Lilly and Company (US), AstraZeneca (UK), Bristol-Myers Squibb Company (US), GlaxoSmithKline plc (UK), Pfizer Inc. (US), Johnson & Johnson Services, Inc. (US), Dr. Reddy’s Laboratories Limited (India), Lupin Pharmaceuticals, Inc. (India), Aurobindo Pharma (India), Zydus Cadila (India), Apotex Inc. (Canada), Teva Pharmaceutical Industries Ltd (Israel) and Sun Pharmaceutical Industries Ltd (India) are some of the key players operating in the market.

Regional Market Summary  

 Bulimia Nervosa Market Share (%), by Region, 2018

Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, and Annual Reports

Geographically, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is anticipated to dominate the  bulimia nervosa market owing to the rising prevalence of bulimia nervosa. According to data published by the National Institute of Mental Health (NIMH) in November 2017, 43.2% people suffering from bulimia nervosa sought treatment for their disorder in the US. Europe is expected to hold the second-largest share of the bulimia nervosa market owing to the presence of major market players such as AstraZeneca and GlaxoSmithKline plc. Asia-Pacific is expected to be the fastest-growing regional market owing to the rising awareness regarding mental disorders and high incidence rate of bulimia nervosa. The bulimia nervosa market in the Middle East & Africa is expected to hold the least share during the forecast period.  

Market for Bulimia Nervosa, by Disorder Type

• Purging


• Non-Purging

Market for Bulimia Nervosa, by Drug Type

• Antidepressants


• Antipsychotics


• Others

Market for Bulimia Nervosa, by Route of Administration

• Oral


• Intravenous


• Others

Market for Bulimia Nervosa, by End User

• Hospitals and Clinics


• Homecare Settings


• Specialty Centers


• Others

Market  for Bulimia Nervosa, by Region

• Americas




• North America


• US


• Canada


• Latin America

• Europe




• Western Europe


• Germany


• France


• Italy


• Spain


• UK


• Rest of Western Europe


• Eastern Europe

• Asia-Pacific




• Japan


• China


• India


• Australia


• South Korea


• Rest of Asia-Pacific

• Middle East & Africa




• Middle East


• Africa

Intended Audience

• Biotechnology companies


• Research institutes


• Pharmaceutical companies


• Hospitals and clinics


• Ambulatory surgical centers


• Academic institutes


• Government organizations

Report Scope:

Report Attribute/Metric	Details
Market Size	2018: USD 429.84 Million 2027: Significant Value
CAGR	4.9% (2019-2025)
Base Year	2019
Forecast Period	2020-2027
Historical Data	2018
Forecast Units	Value (USD Million)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	Disorder Type, Drug Type, Route of Administration and End User
Geographies Covered	North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Key Vendors	Allergan, Inc. (Ireland), Eli Lilly and Company (US), AstraZeneca (UK), Bristol-Myers Squibb Company (US), GlaxoSmithKline plc (UK), Pfizer Inc. (US), Johnson & Johnson Services, Inc. (US), Dr. Reddy’s Laboratories Limited (India), Lupin Pharmaceuticals, Inc. (India), Aurobindo Pharma (India), Zydus Cadila (India), Apotex Inc. (Canada), Teva Pharmaceutical Industries Ltd (Israel) and Sun Pharmaceutical Industries Ltd (India)
Key Market Opportunities	drastically changing lifestyle
Key Market Drivers	lack of drugs specifically for the treatment of bulimia nervosa lack of awareness regarding the treatment options